ICIs, involving inhibitors of PD-1, PD-L1, and CTLA-4, can reverse the state of immunosuppression and mobilize the immune cells to attack the tumor instead of targeting the tumor itself (7). The gene discussed is CTLA4; the disease is neoplasm.